Cargando…

Assessment of a developed HPLC-MS/MS approach for determining plasma eupatorin in rats and its application in pharmacokinetics analysis

Eupatorin, a bioactive compound extracted from Java tea (Orthosiphon stamineus), possesses potent anti-cancer, anti-inflammatory and vasodilation activities. To date, no pharmacokinetics studies on eupatorin have yet been performed. Here, we established and validated a sensitive and selective LC-MS/...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Rui, Li, Luya, Zhang, Xiaowei, Zhang, Yuqian, Chen, Yuting, Feng, Xue, Zhang, Lantong, Zhang, Guohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056642/
https://www.ncbi.nlm.nih.gov/pubmed/35518153
http://dx.doi.org/10.1039/d0ra03350b
_version_ 1784697708976537600
author Feng, Rui
Li, Luya
Zhang, Xiaowei
Zhang, Yuqian
Chen, Yuting
Feng, Xue
Zhang, Lantong
Zhang, Guohua
author_facet Feng, Rui
Li, Luya
Zhang, Xiaowei
Zhang, Yuqian
Chen, Yuting
Feng, Xue
Zhang, Lantong
Zhang, Guohua
author_sort Feng, Rui
collection PubMed
description Eupatorin, a bioactive compound extracted from Java tea (Orthosiphon stamineus), possesses potent anti-cancer, anti-inflammatory and vasodilation activities. To date, no pharmacokinetics studies on eupatorin have yet been performed. Here, we established and validated a sensitive and selective LC-MS/MS (liquid chromatography-tandem mass spectrometry) approach for determining plasma eupatorin in rats. Chromatographic fractionation was conducted on a Wonda Cract ODS-2 C18 Column (4.6 mm × 150 mm, 5 μm) with a mobile phase containing aqueous 0.1% formic acid and acetonitrile using a flow rate of 0.8 ml min(−1). In multiple reaction monitoring mode, precursor-to-product ion transitions for quantification of eupatorin and the internal standard were set at 343.1 → 328.1 and 252.0 → 155.9, respectively. The intra- and inter-day precision and accuracy were found to be below 6.72% and within ±8.26% in rat plasma, respectively. Meanwhile, all values of the matrix effect, recovery and stability were within the accepted ranges. Furthermore, we carried out the pharmacokinetic analysis using the developed method. The pharmacokinetic study revealed that while the C(max) (maximum plasma concentration) of eupatorin and time for reaching the C(max) (T(max)) were 974.886 ± 293.898 μg L(−1) and 0.25 h, respectively, the half-life was 0.353 ± 0.026 h. This study will be of great significance to the research on the pharmacology, clinical pharmacy and drug action mechanism of eupatorin.
format Online
Article
Text
id pubmed-9056642
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-90566422022-05-04 Assessment of a developed HPLC-MS/MS approach for determining plasma eupatorin in rats and its application in pharmacokinetics analysis Feng, Rui Li, Luya Zhang, Xiaowei Zhang, Yuqian Chen, Yuting Feng, Xue Zhang, Lantong Zhang, Guohua RSC Adv Chemistry Eupatorin, a bioactive compound extracted from Java tea (Orthosiphon stamineus), possesses potent anti-cancer, anti-inflammatory and vasodilation activities. To date, no pharmacokinetics studies on eupatorin have yet been performed. Here, we established and validated a sensitive and selective LC-MS/MS (liquid chromatography-tandem mass spectrometry) approach for determining plasma eupatorin in rats. Chromatographic fractionation was conducted on a Wonda Cract ODS-2 C18 Column (4.6 mm × 150 mm, 5 μm) with a mobile phase containing aqueous 0.1% formic acid and acetonitrile using a flow rate of 0.8 ml min(−1). In multiple reaction monitoring mode, precursor-to-product ion transitions for quantification of eupatorin and the internal standard were set at 343.1 → 328.1 and 252.0 → 155.9, respectively. The intra- and inter-day precision and accuracy were found to be below 6.72% and within ±8.26% in rat plasma, respectively. Meanwhile, all values of the matrix effect, recovery and stability were within the accepted ranges. Furthermore, we carried out the pharmacokinetic analysis using the developed method. The pharmacokinetic study revealed that while the C(max) (maximum plasma concentration) of eupatorin and time for reaching the C(max) (T(max)) were 974.886 ± 293.898 μg L(−1) and 0.25 h, respectively, the half-life was 0.353 ± 0.026 h. This study will be of great significance to the research on the pharmacology, clinical pharmacy and drug action mechanism of eupatorin. The Royal Society of Chemistry 2020-08-28 /pmc/articles/PMC9056642/ /pubmed/35518153 http://dx.doi.org/10.1039/d0ra03350b Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Chemistry
Feng, Rui
Li, Luya
Zhang, Xiaowei
Zhang, Yuqian
Chen, Yuting
Feng, Xue
Zhang, Lantong
Zhang, Guohua
Assessment of a developed HPLC-MS/MS approach for determining plasma eupatorin in rats and its application in pharmacokinetics analysis
title Assessment of a developed HPLC-MS/MS approach for determining plasma eupatorin in rats and its application in pharmacokinetics analysis
title_full Assessment of a developed HPLC-MS/MS approach for determining plasma eupatorin in rats and its application in pharmacokinetics analysis
title_fullStr Assessment of a developed HPLC-MS/MS approach for determining plasma eupatorin in rats and its application in pharmacokinetics analysis
title_full_unstemmed Assessment of a developed HPLC-MS/MS approach for determining plasma eupatorin in rats and its application in pharmacokinetics analysis
title_short Assessment of a developed HPLC-MS/MS approach for determining plasma eupatorin in rats and its application in pharmacokinetics analysis
title_sort assessment of a developed hplc-ms/ms approach for determining plasma eupatorin in rats and its application in pharmacokinetics analysis
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056642/
https://www.ncbi.nlm.nih.gov/pubmed/35518153
http://dx.doi.org/10.1039/d0ra03350b
work_keys_str_mv AT fengrui assessmentofadevelopedhplcmsmsapproachfordeterminingplasmaeupatorininratsanditsapplicationinpharmacokineticsanalysis
AT liluya assessmentofadevelopedhplcmsmsapproachfordeterminingplasmaeupatorininratsanditsapplicationinpharmacokineticsanalysis
AT zhangxiaowei assessmentofadevelopedhplcmsmsapproachfordeterminingplasmaeupatorininratsanditsapplicationinpharmacokineticsanalysis
AT zhangyuqian assessmentofadevelopedhplcmsmsapproachfordeterminingplasmaeupatorininratsanditsapplicationinpharmacokineticsanalysis
AT chenyuting assessmentofadevelopedhplcmsmsapproachfordeterminingplasmaeupatorininratsanditsapplicationinpharmacokineticsanalysis
AT fengxue assessmentofadevelopedhplcmsmsapproachfordeterminingplasmaeupatorininratsanditsapplicationinpharmacokineticsanalysis
AT zhanglantong assessmentofadevelopedhplcmsmsapproachfordeterminingplasmaeupatorininratsanditsapplicationinpharmacokineticsanalysis
AT zhangguohua assessmentofadevelopedhplcmsmsapproachfordeterminingplasmaeupatorininratsanditsapplicationinpharmacokineticsanalysis